Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema

Table 2

Demographic data, visual acuity, and optical coherence tomography characteristics in four different eGFR groups at baseline.

	A: eGFR >90 ()	B: eGFR 61-90 ()	C: eGFR 30-60 ()	D: eGFR <30()	value
					A vs. B	A vs. C	A vs. D
Age (year)					0.84	0.002	0.50
Sex (female)	61%	67%	48%	42%	0.33	0.37	0.20
Hypertension	65%	57%	100%	74%	0.76	0.004	0.74
HbA1c (%)					0.57	0.77	0.030
DR staging					0.56	0.51	0.92
Mild NPDR	0%	0%	4%	5%
Moderate NPDR	17%	10%	17%	11%
Severe NPDR	26%	19%	39%	26%
Treatment-naive PDR	17%	10%	22%	21%
PDR with PRP	39%	62%	17%	37%
LogMAR of BCVA					0.17	0.97	0.35
CFT (μm)					0.99	0.50	0.54
Intraretinal cysts	83%	95%	91%	100%	0.35	0.67	0.11
Subretinal fluid	22%	24%	26%	5%	1	1	0.20
Injection number					0.018	0.95	0.18

CFT: central foveal thickness; DR: diabetic retinopathy; eGFR: estimated glomerular filtration rate; LogMAR of BCVA: logarithm of the minimum angle of resolution of best-corrected visual acuity; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation.